Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
December 8, 2015
RegMed’s close: rebound and volatility is not a huge surprise
December 8, 2015
Lower open expected. RegMed’s pre-open, more than a few signals resound
November 30, 2015
RegMed’s close: The sector can’t hide from a few things …
November 23, 2015
RegMed’s close: I always worry about spikes in pricing and advance/decline lines
November 23, 2015
Applied Genetic Technologies (AGTC) Orphan Drug Designation for gene therapy to treat Achromatopsia
November 23, 2015
Lower open expected. RegMed’s pre-open, the sector has spiked higher as we await the next inversion
November 20, 2015
RegMed’s close: week-over-week variations are causing investor inertia and speculator devilment
November 19, 2015
RegMed’s close: too frequently, the gain is followed by pain
November 18, 2015
RegMed’s close: seized the upside but, where is the line in the sand of support?
November 18, 2015
Applied Genetic Technologies (AGTC) gets Orphan Status for its treatment of achromatopsia caused by mutations in the CNGA3 gene - BUY
35 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.